Stoke Therapeutics (STOK) Current Assets (2018 - 2026)

Stoke Therapeutics' Current Assets history runs 9 years deep, the most recent figure standing at $366.7 million for Q1 2026.

• On a quarterly basis, Current Assets fell 2.41% year-over-year to $366.7 million in Q1 2026; TTM through Mar 2026 was $366.7 million, a 2.41% decrease from a year earlier, with the FY2025 full-year figure at $305.7 million, up 31.34% from the prior year.
• Current Assets rose to $366.7 million in Q1 2026 per STOK's latest filing, from $305.7 million in the prior quarter.
• Across five years, Current Assets topped out at $375.7 million in Q1 2025 and bottomed at $193.3 million in Q1 2024.
• The 5-year median for Current Assets is $270.0 million (2025), against an average of $272.5 million.
• Across the five-year window, Current Assets dropped 28.48% in 2024 and jumped 94.4% in 2025, its largest moves.
• Year by year, Current Assets stood at $244.1 million in 2022, then retreated by 11.77% to $215.3 million in 2023, then rose by 8.09% to $232.8 million in 2024, then soared by 31.34% to $305.7 million in 2025, then increased by 19.95% to $366.7 million in 2026.
• Per Business Quant, the three latest STOK Current Assets figures stand at $366.7 million (Q1 2026), $305.7 million (Q4 2025), and $272.4 million (Q3 2025).